Sudeep Pharma Limited has entered the third and final day of its initial public offering (IPO) on November 25, 2025. The book-building issue is valued at Rs 895 crore and includes a fresh issue of 0.16 crore shares worth Rs 95 crore along with an offer for sale (OFS) of 1.35 crore shares worth Rs 800 crore. Investors have shown keen interest in the IPO due to the company’s growth prospects and market positioning in the pharmaceutical sector.
The price band for Sudeep Pharma’s IPO was fixed between Rs 563 and Rs 593 per share, with the final issue price determined at Rs 593. Market analysts are monitoring the Grey Market Premium (GMP) closely to gauge investor sentiment, with trends on the third subscription day indicating strong participation from retail and institutional investors alike.
The IPO subscription window opened on November 21, 2025, and will close on November 25, 2025. According to market updates, Sudeep Pharma’s shares have attracted attention from a mix of retail, non-institutional, and qualified institutional buyers, reflecting confidence in the company’s business model, product portfolio, and growth strategy.
Investors can expect the allotment of shares on November 26, 2025, with refunds scheduled for November 27, 2025. The company’s tentative listing date on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) is November 28, 2025. These dates are critical for subscribers to plan their investment strategies and assess post-listing performance.
The IPO proceeds will be utilized for various purposes, including expansion of manufacturing facilities, working capital requirements, and strategic initiatives aimed at strengthening Sudeep Pharma’s market presence. The fresh issue portion will directly fund these growth projects, while the OFS allows existing shareholders to partially monetize their holdings.
Market experts suggest that Sudeep Pharma’s IPO is a reflection of investor confidence in the pharmaceutical sector, which has seen increased demand and strategic importance in recent years. The company’s operational track record, financial performance, and future growth prospects are key factors driving participation in this public offering.
In conclusion, Sudeep Pharma’s IPO has reached its final subscription day with strong market interest and competitive Grey Market Premiums. The Rs 895 crore issue, with shares priced at Rs 593 each, is expected to be allotted on November 26, followed by refunds on November 27 and listing on BSE and NSE on November 28. Investors and market participants will closely watch post-listing movements, subscription trends, and GMP updates to evaluate the performance of Sudeep Pharma in the stock market.
